What are the signs and symptoms of Indolent Systemic Mastocytosis (ISM), Bone Marrow Mastocytosis (BMM), and Aggressive Systemic Mastocytosis (ASM)?

Signs and Symptoms of Indolent Systemic Mastocytosis (ISM), Bone Marrow Mastocytosis (BMM), and Aggressive Systemic Mastocytosis (ASM)

ISM presents predominantly with skin lesions (85% of patients) and cutaneous symptoms (78%), while constitutional symptoms are uncommon (15%); BMM lacks skin involvement but has the highest rate of mediator-release symptoms (86%); ASM is characterized by organ damage manifestations including cytopenias, hepatic dysfunction, skeletal involvement, splenic dysfunction, or gastrointestinal malabsorption. 1, 2

Indolent Systemic Mastocytosis (ISM)

Cutaneous Manifestations

• Skin lesions present in 85% of patients, typically appearing as urticaria pigmentosa-like lesions 1
• Cutaneous symptoms affect 78% of patients, including flushing and pruritus 1

Mast Cell Mediator-Release Symptoms

• Constitutional symptoms are uncommon, occurring in only 15% of patients 1, 2
• Mediator-related symptoms affect 67% of ISM patients, including: 1
  • Flushing episodes 1
  • Pruritus 1
  • Gastrointestinal symptoms (dyspepsia, diarrhea, abdominal pain) 3
  • Palpitations 3
  • Bone pain 3, 4
  • Headache 4
  • Lightheadedness 4

Anaphylaxis Risk

• Life-threatening anaphylaxis can occur, particularly following Hymenoptera (bee/wasp) stings or other triggers, requiring immediate epinephrine administration 1, 5, 3
• Some patients present with severe hypotensive episodes as the initial manifestation 5

Key Clinical Features

• Low mast cell burden with no organ damage (absence of C-findings) 1, 2
• Younger age at presentation compared to other SM subtypes 1
• Elevated serum tryptase (typically >20 ng/mL but <200 ng/mL) 1, 5

Bone Marrow Mastocytosis (BMM)

Distinguishing Characteristics

• BMM is a specific subvariant of ISM where mast cell infiltration is strictly confined to the bone marrow 1, 2
• Complete absence of skin lesions or multiorgan visceral involvement 1, 2

Symptom Profile

• Highest incidence of mast cell mediator-release symptoms at 86%, compared to 67% in ISM and 50% in smoldering SM 1, 2
• Symptoms include the full spectrum of mediator-related manifestations (flushing, pruritus, gastrointestinal complaints, cardiovascular symptoms) 1

Diagnostic Challenge

• Lack of typical skin lesions makes diagnosis challenging, requiring high index of suspicion in patients with unexplained mediator-related symptoms or anaphylaxis 5, 3
• Elevated serum tryptase is a critical diagnostic clue in the absence of skin findings 5

Aggressive Systemic Mastocytosis (ASM)

Defining Feature: C-Findings (Organ Damage)

ASM requires the presence of one or more C-findings, which represent organ damage from neoplastic mast cell infiltration: 1, 2

Hematologic Manifestations

• Cytopenias due to bone marrow dysfunction: 1
  • Absolute neutrophil count <1 × 10⁹/L
  • Hemoglobin <10 g/dL
  • Platelet count <100 × 10⁹/L
• Bone marrow fibrosis 4

Hepatic Involvement

• Palpable hepatomegaly with impaired liver function 1
• Ascites 1
• Portal hypertension 1

Skeletal Manifestations

• Large osteolytic lesions 1
• Pathologic fractures 1, 6
• Severe osteoporosis 6, 4
• Bone pain 6, 4

Splenic Involvement

• Palpable splenomegaly with hypersplenism 1
• Hepatosplenomegaly 6, 4

Gastrointestinal Manifestations

• Malabsorption with hypoalbuminemia 1, 6
• Weight loss due to gastrointestinal mast cell infiltrates 1
• Abdominal pain 4
• Diarrhea 4

Cutaneous Features

• Skin lesions are less common in ASM compared to ISM 1
• When present, may include urticaria pigmentosa 4

Laboratory Abnormalities

• Elevated serum tryptase and histamine 4
• Eosinophilia may be present 4
• Bone marrow angiogenesis 4

Critical Clinical Pitfalls

Diagnostic Considerations

• In patients lacking skin lesions, mastocytosis is frequently overlooked or misdiagnosed as endocrinologic, allergic, or other internal disorders 5
• Elevated serum tryptase (>20 ng/mL) is a critical diagnostic clue, particularly in patients with unexplained anaphylaxis or mediator-related symptoms without skin involvement 5, 3

Distinguishing ASM from SM-AHN

• If C-findings are present along with an associated hematologic neoplasm (AHN), the diagnosis is SM-AHN, not ASM, even if organ damage appears related to mast cells 1, 2
• This distinction has important prognostic and therapeutic implications 2

Symptom Assessment Tools

• The Mastocytosis Quality-of-Life Questionnaire (MQLQ) and Mastocytosis Symptom Assessment Form (MSAF) should be used for baseline assessment and monitoring in ISM patients 1, 7